Navigation Links
Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo
Date:11/15/2010

CHICAGO, Nov. 15, 2010 /PRNewswire/ -- Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that 12-month data from its Phase 2 CUPID clinical trial of MYDICAR® demonstrated significant improvements in clinical outcomes and key disease markers in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy.

"Physicians and patients have long believed that a failing heart cannot be repaired, but the CUPID trial with MYDICAR adds support to other recent studies suggesting that the deterioration of heart function can indeed be slowed down, resulting in reduced hospitalizations and other cardiovascular events," said Donna Mancini, M.D., medical director of cardiac transplantation at NewYork-Presbyterian Hospital/Columbia University Medical Center and professor of medicine at Columbia University College of Physicians and Surgeons, who presented the study's one-year results during the American Heart Association Scientific Sessions 2010. "I am very encouraged that our approach of restoring a critical enzyme that is depleted in such advanced patients will enhance our understanding of the human heart."

The study of 39 patients met its primary safety and efficacy endpoints at 6 months for high dose MYDICAR versus placebo.  Additionally, after 12 months of receiving a single infusion of MYDICAR, patients treated with the highest dose versus placebo had an 88 percent risk reduction (Hazard Ratio = 0.12, P=0.003), of major cardiovascular events such as:

  • Death
  • Need for left ventricular assist device (LVAD) or cardiac transplant
  • Episodes of worsening of heart failure
  • Number of heart failure-related hospitalizations

The mean duration of hospitalization in the MYDICAR high dose group during the 12-month period was 0.4 days per pat
'/>"/>

SOURCE Celladon Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The Journal of Cardiac Failure Publishes Results From Celladon Corporations First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure
2. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
3. Pharmos Corporation Reports 2008 Second Quarter Results
4. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
5. Genaera Corporation Announces Second Quarter Financial Results
6. MannKind Corporation Reports Second Quarter Financial Results
7. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
8. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
9. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
11. Mymetics Corporation Important Shareholders Information Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Boston, MA (PRWEB) May 04, 2015 ... solutions for drug discovery and life science research, ... 5.0 , the latest version of its enterprise ... for biopharma R&D enables more efficient discovery and ... holistic approach to integrate and address protein optimization ...
(Date:5/4/2015)... 4, 2015   Tocagen Inc. , a ... from Tocagen,s ongoing investigational studies were presented at ... American Association of Neurological Surgeons (AANS)/Congress of Neurological ... 2015, in Washington, D.C. ... meeting with FDA and continues to advance towards ...
(Date:5/1/2015)... (PRWEB) May 01, 2015 OncoTAb, ... (UNC Charlotte) spin-out company, announced that Pinku Mukherjee, Ph.D. ... the UNC Board of Governors’ highest faculty honor. Mukherjee ... humanity’s welfare , for her innovative research and development ... Gardner Award represents a crowning moment in my scientific ...
(Date:5/1/2015)... , May 1, 2015 ... Genetic Technologies Ltd (NASDAQ: GENE ), Agilent ... Scientific Inc. (NYSE: TMO ), Sequenom Inc. ... PKI ). Free research report on Genetic ... On Thursday, April 30, 2015, the NASDAQ Composite ...
Breaking Biology Technology:Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5OncoTAb CSO Awarded the University of North Carolina’s O. Max Gardner Award 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5
... Multiporator , , , , , , , ... Protocol No. 4308 915.050 11/2001 , , , ... , Cell line , ... Transfection with , pcDNA3.1/V5-His-TOPO (in bidistilled H 2 O), ...
... , Multiporator / Electroporator 2510 , , , , , , ... Transformation Protocol , Protocol No. 4308 915.536 01/2002 , ... , , , , , ... , , Cell type ...
... , , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.533 01/2002 , ... , , , , , ... , Cell type , Bacteria, ...
Cached Biology Technology:721.221 2Ustilago maydis 2Ustilago maydis 3Staphylococcus aureus 2
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the addition ... Report" report to their offering. This report analyzes ... by the following Segments: Face Biometrics, and Voice Biometrics. The report ... , Japan , Europe , ... & Africa , and Latin America ...
(Date:3/23/2015)... BOSTON, Mass , March 23, 2015 SoundView ... shipment of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView ... world user feedback on their experience with the Wocket in ... experience at CVS, Whole Foods and other retailers, making both ... Kris Tuttle also says, "If the company meets ...
(Date:3/23/2015)... Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... on CNBC television starting March 30 th . ... in New York markets. ... are excited about our new ad campaign following the recent ...
Breaking Biology News(10 mins):Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... 19, 2013  Organovo Holdings, Inc. (NYSE MKT: ONVO) (" Organovo ... bioprinting technology, has been invited to present at the 25th ... New York December 3-4, 2013. ... Murphy , will be presenting on Wednesday, December 4, at ...
... great white shark, a major apex predator made famous by ... species capturing an extraordinary amount of public fascination. An intriguing ... way to address this is to explore the genetic makeup ... scientists from Nova Southeastern University,s (NSU) Save Our Seas Shark ...
... of annual change in sea-ice cover can been seen in ... new study from the University of Toronto Mississauga (UTM). ... used to track changes in Arctic sea ice," says Jochen ... Physical Sciences. "We found the algal record shows a dramatic ...
Cached Biology News:Organovo to Present at the 25th Annual Piper Jaffray Healthcare Conference 2Genome scale view of great white shark uncovers unexpected and distinctive features 2Genome scale view of great white shark uncovers unexpected and distinctive features 3Underwater 'tree rings' 2
... Create 100% capped transcripts with the ... higher yields of 100% capped (versus 40% ... mRNA messages in about 2 hours. mScript™ ... has been shown to be up to ...
Porcine parvovirus and mycoplasma tested. Contains 0.5 g/L of trypsin (1:250) and 0.2 g/L of EDTA4Na in Hanks' Balanced Salt Solution without CaCl2 MgCl2 6H2O and MgSO4 7H2O. Contains phenol red....
...
...
Biology Products: